Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyridoxine Adjuvant Therapy in Type 2 Diabetes
NCT05918068Completed
- Sponsor
- Al-Rasheed University College
- Start
- Nov 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of pyridoxine in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Al-Rasheed University College. Primary endpoints: Fasting Plasma Glucose at 1 month and Glycated Hemoglobin at 1 month. Started Nov 2022; status: completed.
02
Drugs
pyridoxine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05918068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05918068.